{"id":"W2102195694","doi":"10.1016/s1470-2045(14)70244-x","title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":305,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"University of Arizona Cancer Center; Amgen","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Population; Progression-free survival; Randomized controlled trial; Oncology; Phases of clinical research; Adverse effect; Clinical trial; Surgery; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001714377,0.001999001,0.003936764,0.0004363808,0.0004455248,0.001193103,0.00100362,0.002246747,0.007724175],"category_scores_gemma":[0.001819461,0.0007350305,0.002488927,0.0004525069,0.001302899,0.001324336,0.0004701555,0.003621635,0.001384184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007242424,"about_ca_system_score_gemma":0.0009560065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001019291,"about_ca_topic_score_gemma":0.002151662,"domain_scores_codex":[0.9994487,0.0002631298,0.00002905993,0.0000980613,0.0000378521,0.0001231206],"domain_scores_gemma":[0.9992403,0.0002114766,0.0001633038,0.00007291671,0.00004229726,0.0002696935],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9823806,0.001775283,0.0002177676,0.0007285426,0.0009008517,0.00003071462,0.00003592636,0.000240356,0.001929535,0.0001116879,0.001048625,0.01060014],"study_design_scores_gemma":[0.9814198,0.01720198,0.0004648476,0.00002370908,0.0001983663,0.00001937383,0.000009382154,0.0001106445,0.0001131727,0.00008886118,0.0003406844,0.000009205285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719648,0.01298113,0.001300489,0.001766892,0.00178193,0.004566579,0.002221922,0.0003706206,0.003045724],"genre_scores_gemma":[0.9711488,0.007374024,0.002212328,0.002487424,0.0008762668,0.006477694,0.002100004,0.00008022945,0.007243179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007724175,"threshold_uncertainty_score":0.02583992,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05990155337821918,"score_gpt":0.3706850085049904,"score_spread":0.3107834551267712,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}